Health Canada Greenlights Kashiv’s Pegfilgrastim Biosimilar

The Drug Will Be Sold As Pexegra By Local Partner JAMP Pharma

 
• By Adam Zamecnik
  
Red pin on Canada on the map
Denosumab key patents will expire in 2025 • Source: Shutterstock

More from Biosimilars

More from Generics Bulletin